AstraZeneca COVID-19 vaccine leaflet

Package leaflet: Information for the recipient COVID-19 Vaccine AstraZeneca COVID-19 Vaccine (ChAdOx1-S [recombinant]), last revised 12/2020

Every person who received a COVID-19 vaccine dose receives a leaflet from the manufacturer about the vaccine, including possible side effects. This double sided leaflet contains information of how to store the vaccine and what the packaging looks like and the active ingredients in the vaccine.

Developed in collaboration by the Oxford Vaccine Group and the biopharmaceutical company AstraZeneca drew on a decade of research and was developed, tested and approved in less than a year. The active element in the vaccine is made from an adenovirus that causes the common cold in chimpanzees, which was modified so that it cannot cause an infection. It is used to deliver the genetic code for the coronavirus spike protein to prime the recipient's body for an infection of COVID-19. The vaccine was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) on 30 December 2020. It was the second vaccine to be approved.